TransMedics Group (TMDX) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
10x Genomics (TXG) has outperformed TransMedics Group (TMDX) over the past year, gaining 540.3% versus a loss of 33.1%. Over five years, TMDX leads with a +197.6% price change compared with -49.2% for TXG. 10x Genomics is the larger company by market cap ($10.07 billion vs $2.74 billion), about 3.7 times the size, while TransMedics Group is growing revenue faster (+37.1% vs +5.2%).
On valuation, TransMedics Group trades at a lower forward P/E (35.0x vs 1008.0x for 10x Genomics). TransMedics Group converts more of its revenue into profit, with a net margin of 31.4% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TMDX | TXG |
|---|---|---|
| Share price | $79.00 | $77.28 |
| Market cap | $2.74B | $10.07B |
| 1-day change | -2.55% | +1.55% |
| YTD return | -35.06% | +373.82% |
| 1-year return | -33.08% | +540.27% |
| 5-year return | +197.55% | -49.25% |
| P/E ratio (TTM) | 20.47 | — |
| Forward P/E | 35.05 | — |
| EPS (TTM) | $3.86 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $605.49M | $642.82M |
| Revenue growth (YoY) | +37.13% | +5.25% |
| Net income (latest FY) | $190.29M | $-43.54M |
| Gross margin | 59.92% | 69.05% |
| Operating margin | 17.93% | -9.49% |
| Net margin | 31.43% | -6.77% |
| 52-week high | $156.00 | $102.81 |
| 52-week low | $60.11 | $11.16 |
| Distance from 52-week high | -49.36% | -24.83% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +26.35% | -12.69% |
| Average volume | 820.41K | 3.29M |
| Shares outstanding | 34.68M | 120.21M |
| Employees | 898 | 1,178 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 10x Genomics is about 3.7 times larger than TransMedics Group by market value ($10.07B vs $2.74B).
- TXG has outperformed TMDX by 573.3 percentage points over the past year.
- TransMedics Group is more profitable, keeping 31.4 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
- TransMedics Group grew revenue faster in its latest fiscal year (+37.13% vs +5.25%).
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Healthcare · Medical Devices · 1,178 employees
TMDX vs TXG FAQ
Which is bigger, TransMedics Group or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $10.07B compared with $2.74B for TransMedics Group (TMDX).
Which stock has performed better over the past year, TMDX or TXG?
TXG returned +540.27% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are TransMedics Group and 10x Genomics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.